Tumor immunology and cancer vaccines

Por Khleif, Samir N.
Publicado em 2005

Therapeutic Vaccines for Gastrointestinal Cancers

Por Rahma, Osama E., Khleif, Samir N.
Publicado em 2011

The FDA Guidance on therapeutic cancer vaccines: the need for revision to include preventive cancer vaccines or for a new guidance dedicated to them

Por Finn, Olivera J., Khleif, Samir N., Herberman, Ronald B.
Publicado no Cancer Prev Res (Phila) (2015)

AKT inhibition mitigates terminal differentiation and preserves central memory phenotype of CD8 T cells

Por Abu Eid, Rasha, Friedman, Kevin, Mkrtichyan, Mikayel, Khleif, Samir N
Publicado no J Immunother Cancer (2014)

Is the “3+3” dose escalation phase 1 clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design

Por Rahma, Osama E., Gammoh, Emily, Simon, Richard M., Khleif, Samir N.
Publicado em 2014

High-dose treatment with ADXS11-001, a listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy, in women with cervical cancer

Por Ghamande, Sharad, Mauro, David, Price, Cheryl, Wheatley, Donna, Janik, John, Khleif, Samir N
Publicado no J Immunother Cancer (2015)

Episomal expression of truncated listeriolysin O in LmddA-LLO-E7 vaccine enhances antitumor efficacy by preferentially inducing expansions of CD4(+)FoxP3(−) and CD8(+) T cells

Por Chen, Zhisong, Ozbun, Laurent, Chong, Namju, Wallecha, Anu, Berzofsky, Jay A., Khleif, Samir N.
Publicado em 2014

Functional redundancy of PI3K isoforms in conventional T cells provides a selective Treg-targeting strategy through inhibition of PI3K-delta isoform

Por Ahmad, Shamim, Mkrtichyan, Mikayel, Eid, Rasha Abu, Shrimali, Rajeev, Doroodchi, Atbin, Khleif, Samir N
Publicado no J Immunother Cancer (2014)

Immuno-Oncology biomarkers 2010 and beyond: Perspectives from the iSBTc/SITC biomarker task force

Por Balwit James M, Marincola Francesco M, Khleif Samir N, Disis Mary L, Butterfield Lisa H
Publicado em 2010-12-01

Incomplete penetrance of familial retinoblastoma linked to germ-line mutations that result in partial loss of RB function

Por Otterson, Gregory A., Chen, Wei-dong, Coxon, Amy B., Khleif, Samir N., Kaye, Frederic J.
Publicado em 1997

Immuno-Oncology biomarkers 2010 and beyond: Perspectives from the iSBTc/SITC biomarker task force

Por Butterfield, Lisa H, Disis, Mary L, Khleif, Samir N, Balwit, James M, Marincola, Francesco M
Publicado em 2010

Molecular Characterization of Antigen-Peptide Pulsed Dendritic Cells: Immature Dendritic Cells Develop a Distinct Molecular Profile when Pulsed with Antigen Peptide

Por Yang, Amy X., Chong, Numju, Jiang, Yufei, Catalano, Jennifer, Puri, Raj K., Khleif, Samir N.
Publicado em 2014

Preamble to the 2015 SITC immunotherapy biomarkers taskforce

Por Butterfield, Lisa H, Disis, Mary L, Fox, Bernard A, Khleif, Samir N, Marincola, Francesco M
Publicado no J Immunother Cancer (2015)

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy

Por Mkrtichyan, Mikayel, Chong, Namju, Abu Eid, Rasha, Wallecha, Anu, Singh, Reshma, Rothman, John, Khleif, Samir N
Publicado em 2013

Akt1 and -2 inhibition diminishes terminal differentiation and enhances central memory CD8(+) T-cell proliferation and survival

Por Abu Eid, Rasha, Friedman, Kevin M, Mkrtichyan, Mikayel, Walens, Andrea, King, William, Janik, John, Khleif, Samir N
Publicado no Oncoimmunology (2015)

Focus on the target: the tumor microenvironment, Society for Immunotherapy of Cancer Annual Meeting Workshop, October 24th-25th 2012

Por Sunay, Melek Erdinc, Marincola, Francesco, Khleif, Samir N, Silverstein, Samuel C, Fox, Bernard A, Galon, Jerome, Emens, Leisha A
Publicado em 2013

The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors

Por Rahma, Osama E, Hamilton, J Michael, Wojtowicz, Malgorzata, Dakheel, Omar, Bernstein, Sarah, Liewehr, David J, Steinberg, Seth M, Khleif, Samir N
Publicado em 2014

Immune combinational therapy targeting OX40 and IDO synergistically enhances efficacy of a cancer vaccine

Por Berrong, Zuzana, Ahmad, Shamim, Abu Eid, Rasha, El Andaloussi, Abdeljabar, Sen, Tanusree, Stewart, Ross, Hammond, Scott A, Shrimali, Rajeev, Mkrtichyan, Mikayel, Khleif, Samir N
Publicado no J Immunother Cancer (2014)

Regulatory Approval of Cancer Risk-reducing (Chemopreventive) Drugs: Moving What We Have Learned into the Clinic

Por Meyskens, Frank L., Curt, Gregory A., Brenner, Dean E., Gordon, Gary, Herberman, Ronald B., Finn, Olivera, Kelloff, Gary J., Khleif, Samir N., Sigman, Caroline C., Szabo, Eva
Publicado em 2011

Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer

Por Rahma, Osama E, Herrin, Vincent E, Ibrahim, Rami A, Toubaji, Anton, Bernstein, Sarah, Dakheel, Omar, Steinberg, Seth M, Eid, Rasha Abu, Mkrtichyan, Mikayel, Berzofsky, Jay A, Khleif, Samir N
Publicado no J Transl Med (2014)